Systemic Medications of Dermatological Importance in COVID-19

September 2020 | Volume 19 | Issue 9 | Original Article | 889 | Copyright © September 2020

Published online August 21, 2020

Robert A. Schwartz MD MPH DSc (Hon) FRCP (Edin),a Aseem Sharma MD,b Torello Lotti,c Jacek C. Szepietowski MD,d Sunmeet Sandhu MD,e Mohamad Goldust MDf

aRutgers New Jersey Medical School, Newark, NJ bSkin Saga Centre for Dermatology, Mumbai, India cUniversity of Studies Guglielmo Marconi, Rome, Italy dWroclaw Medical University, Wroclaw, Poland eArmed Forces Medical College, Pune, India fUniversity Hospital Basel, Basel, Switzerland

23. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787. [Epub ahead of print] PubMed PMID: 32251768; PubMed Central PMCID: PMC7129059.
24. Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment? J Am Acad Dermatol. 2020. pii: S0190-9622(20)30557-0. doi: 10.1016/j.jaad.2020.04.017. [Epub ahead of print] PubMed PMID: 32283237; PubMed Central PMCID: PMC7146719.
25. Schwartz RA, Al-Qubati Y, Zieleniewski L, Shah R, Kapila R: Onchoceriasis (river blindness): larva-induced eczema (onchodermatitis) from an important oculocutaneous tropical disease spilling over into North America and Europe. Int J Dermatol. 2019 Sep 12. doi: 10.1111/ijd.14614. [Epub ahead of print] PMID: 31513297.
26. Schwartz RA, Suskind RM. Azithromycin and COVID-19 Prompt Early Use at First Signs of this Infection in Adults and Children: An Approach Worthy of Consideration. Dermatol Ther. 2020 Jun 8:e13785. doi: 10.1111/dth.13785. Online ahead of print. PMID: 32510734
27. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2022;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. PubMed PMID: 32171062; PubMed Central PMCID: PMC7118626.
28. Amici C, Di Coro A, Ciucci A, Chiappa L, Castilletti C, Martella V, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther. 2006;11(8):1021-30.
29. Sodhi M, Etminan M. Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacother J Hum Pharmacol Drug Ther. 2020. doi: 10.1002/ phar.2395. [Epub ahead of print] PubMed PMID: 32267566.
30. The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID-19) pneumonia - full text view - [Internet]. [cited 2020 Apr 25]. Available from: show/NCT04273529.
31. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Pública. 2020;44:e40. doi: 10.26633/ RPSP.2020.40. eCollection 2020. PubMed PMID: 32256547; PubMed Central PMCID: PMC7105280.
32. Almutairi N, Schwartz RA. COVID-19 with Dermatologic Manifestations and Implications: An Unfolding Conundrum. Dermatol Ther 2020 May 9:e13544. doi:10.1111/dth.13544. Online ahead of print. PMID: 32385869


Mohamad Goldust MD